US009511128B2

(12) **United States Patent**
Singh et al.

(10) **Patent No.: US 9,511,128 B2**
(45) **Date of Patent: Dec. 6, 2016**

(54) **IMMUNOGENIC EPITOPES FOR IMMUNOTHERAPY**

(71) Applicant: **IMMATICS BIOTECHNOLOGIES GMBH**, Tuebingen (DE)

(72) Inventors: **Harpreet Singh**, Tubingen (DE); **Steffen Walter**, Dusslingen (DE); **Toni Weinschenk**, Aichwald (DE); **Norbert Hilf**, Kirchentellinsfurt (DE); **Oliver Schoor**, Tubingen (DE); **Claudia Trautwein**, Wuelfrath (DE)

(73) Assignee: **IMMATICS BIOTECHNOLOGIES GMBH**, Tuebingen (DE)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/138,421**

(22) Filed: **Dec. 23, 2013**

(65) **Prior Publication Data**

US 2014/0271692 A1 Sep. 18, 2014

Related U.S. Application Data

(62) Division of application No. 12/915,473, filed on Oct. 29, 2010, now Pat. No. 8,669,230, which is a division of application No. 12/180,045, filed on Jul. 25, 2008, now Pat. No. 8,080,634.

(60) Provisional application No. 60/953,161, filed on Jul. 31, 2007.

(30) **Foreign Application Priority Data**

Jul. 27, 2007 (EP) 07014797

(51) **Int. Cl.**

C07K 14/00	(2006.01)
A61K 39/00	(2006.01)
C07K 14/47	(2006.01)
C07K 14/495	(2006.01)
C12N 9/02	(2006.01)
A61K 35/17	(2015.01)
C07K 7/06	(2006.01)
C07K 7/08	(2006.01)
C07K 19/00	(2006.01)
C07K 14/725	(2006.01)
C07K 16/40	(2006.01)
C12N 5/0783	(2010.01)
C12N 9/10	(2006.01)

(52) **U.S. Cl.**

CPC ***A61K 39/0011*** (2013.01); ***A61K 35/17*** (2013.01); ***C07K 7/06*** (2013.01); ***C07K 7/08*** (2013.01); ***C07K 14/47*** (2013.01); ***C07K 14/4748*** (2013.01); ***C07K 14/495*** (2013.01); ***C07K 14/7051*** (2013.01); ***C07K 16/40*** (2013.01); ***C07K 19/00*** (2013.01); ***C12N 5/0638*** (2013.01); ***C12N 9/0036*** (2013.01); ***C12N 9/13*** (2013.01); *A61K 2039/5158* (2013.01); *A61K 2039/572* (2013.01); *C07K 2317/34* (2013.01); *C07K 2319/00* (2013.01); *C12N 2502/1157* (2013.01); *C12Y 208/02011* (2013.01)

(58) **Field of Classification Search**
None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

6,531,447	B1	3/2003	Ruben et al.
7,396,904	B2	7/2008	Weinschenk et al.
2002/0048763	A1	4/2002	Penn et al.
2006/0123505	A1	6/2006	Kikuchi et al.

FOREIGN PATENT DOCUMENTS

WO	01854733	8/2001
WO	02/059609	8/2002
WO	02078524	10/2002
WO	03000113	1/2003
WO	2004030615	4/2004
WO	2005044990	5/2005
WO	2005116051	12/2005
WO	2007028574	3/2007

OTHER PUBLICATIONS

Walter et al, Abstract No. 753 American Assn for Cancer Research Annual Meeting Apr. 2001.*
Haigh et al Oncology vol. 13 p. 1561 (1999).*
Fikes, J., Ph.D, The Rational Design of T-Cell Epitopes With Enhanced Immunogenicity, Handbook of Cancer pp. 11-17 (edits by Morse, M.A. et al. 2004).
Fong, L, et al., Proc. Natl. Acad. Sci. U.S.A, vol. 98, No. 15, pp. 8809-8814 (2001).
Topalian, S. L. et al., Cancer Immunotherapy Comes of Age, Journal of Clinical Oncology, vol. 29, No. 36, pp. 4828-3620, 2011).
Walter, S. et al., In vitro veritas: Successful in vitro prediction of clinical immunogenicity of two cancer vaccines, No. 753, American Association for Cancer Research Annual Meeting (Apr. 2011).
McDevitt H., "Specific antigen vaccination to treat autoimmune disease," PNAS, Oct. 5, 2004, vol. 101, pp. 14.627-14630.
Mihalyo et al., "In Vivo Cyclophosphamide and IL-2 Treatment Impedes Self-Antigen-Induced Effector CD4 Cell Tolerization: Implications for Adoptive Immunotherapy," J. Immunol, 2004, pp. 5338-5345.

(Continued)

Primary Examiner — Sheela J Huff
(74) *Attorney, Agent, or Firm* — McBee Moore Woodward Vanik IP LLC

(57) **ABSTRACT**

The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor immune responses. The present invention relates to novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells which can be used in vaccine compositions for eliciting anti-tumor immune responses.

8 Claims, 23 Drawing Sheets